Pharmacokinetics — what the body does to the drug — and the blood-brain barrier (BBB) — what restricts drug entry into the CNS — are the dual gatekeepers of every neurologic medication. A drug that has perfect pharmacodynamic properties for treating a CNS disease is useless if it cannot cross the BBB to reach its target. A drug with ideal molecular structure may fail clinically because of unfavorable absorption, distribution, metabolism, or elimination characteristics. This page covers the core PK principles and the BBB biology that determine which drugs reach the brain and at what concentration.

Pharmacokinetic Principles

Absorption

Oral bioavailability is the single most important determinant for chronic neurologic drugs. Factors affecting absorption:

  • Lipid solubility: greater lipid solubility → better passive intestinal absorption.
  • pH and ionization: drugs are absorbed best when uncharged; weak acids better absorbed in the stomach, weak bases in the small intestine.
  • P-glycoprotein efflux: actively pumps some drugs back into the gut lumen, limiting absorption.
  • First-pass hepatic metabolism: reduces oral bioavailability of many drugs (large reduction for drugs like buprenorphine, propranolol; less for drugs like levetiracetam).
  • Food effects: can increase (fatty meal for some drugs), decrease (some bisphosphonates), or have no effect on absorption.
  • Gastroparesis in Parkinson disease: can dramatically alter levodopa absorption.
  • Bariatric surgery, malabsorption syndromes: reduce absorption of many drugs.

Distribution

  • Volume of distribution (Vd): a calculated value relating dose to plasma concentration; higher Vd suggests extensive tissue distribution.
  • Plasma protein binding: most drugs bind to albumin or α1-acid glycoprotein; only unbound drug is active.
  • Lipid solubility and partitioning: highly lipid-soluble drugs distribute extensively into fat (long half-life of accumulation/release).
  • Brain distribution: requires BBB crossing; specialized property covered below.

Metabolism

Covered in detail in the Metabolism & CYP450 page. Key points:

  • Phase I reactions (oxidation, reduction, hydrolysis): cytochrome P450 enzymes dominant.
  • Phase II reactions (conjugation): glucuronidation, sulfation, acetylation.
  • Many drugs require hepatic metabolism to be cleared; renal clearance for water-soluble drugs and metabolites.

Elimination and Half-Life

  • First-order kinetics: most drugs at therapeutic doses; constant fraction eliminated per unit time.
  • Zero-order (saturable) kinetics: phenytoin classical example; constant amount eliminated per unit time.
  • Half-life (t½): time for plasma concentration to fall by half.
  • Steady state: reached after 4-5 half-lives; the time before therapeutic effect is fully established.
  • Loading dose: rapidly achieves therapeutic concentration when initial effect is needed (anticoagulants, anti-seizure medications in status epilepticus).
  • Maintenance dose: matches elimination rate; depends on half-life.

The Blood-Brain Barrier

Structure

The BBB is formed by:

  • Tight junctions between endothelial cells: extraordinarily tight, with claudins, occludins, and zonula occludens proteins.
  • Specialized astrocytic endfeet investing the basement membrane.
  • Pericytes regulating endothelial function.
  • Active transport systems: for glucose (GLUT1), amino acids (LAT1), neurotransmitter precursors.
  • Active efflux pumps: P-glycoprotein, MRPs, BCRP — actively expel drugs from brain back to blood.

What Crosses the BBB?

  • Small, lipophilic, neutral molecules: cross most easily.
  • Drugs with mw < 400-500 Da: more likely to cross passively.
  • Drugs with high CNS-MPO (multiparameter optimization) score: designed property of newer CNS drugs.
  • Carrier-mediated transport substrates: levodopa (LAT1), gabapentin (transmembrane protein system).
  • Highly protein-bound drugs: only free fraction crosses.

What Doesn’t Cross Well?

  • Large molecules: monoclonal antibodies (lecanemab, donanemab, anti-CD20 mAbs) — penetrate at ~0.1% of plasma concentration. This is why CNS-active mAbs often require high doses.
  • Hydrophilic charged drugs: heparins, dopamine (must give levodopa precursor).
  • P-glycoprotein substrates: actively pumped out; relevant for many opioids, ondansetron, some immunosuppressants.

Strategies to Cross or Bypass the BBB

  • Molecular design: smaller, more lipophilic, fewer hydrogen bonds, neutral or weak basicity.
  • Prodrugs: lipid-soluble forms that cross BBB then convert to active form (levodopa → dopamine in brain).
  • Targeted carriers: leveraging endogenous transport systems (anti-transferrin receptor antibodies — investigational).
  • Intrathecal/intracerebroventricular delivery: nusinersen (intrathecal) for SMA; antibiotics for CNS infection; chemotherapy for leptomeningeal disease.
  • Direct intracerebral injection: gene therapy products.
  • BBB disruption: hyperosmolar mannitol (transient), focused ultrasound (emerging for AD treatment delivery).
  • Inhibiting efflux pumps: investigational; modulators of P-glycoprotein.

Special PK Considerations in Neurology

Drug Penetration of CSF and Brain Parenchyma

CSF and brain parenchyma can have different drug concentrations:

  • Many antibiotics achieve good CSF levels but lower brain parenchymal levels.
  • Inflammation increases BBB permeability — meningitis allows penicillin penetration that healthy BBB doesn’t.
  • For brain abscess (parenchymal infection), drugs that penetrate brain (metronidazole, ceftriaxone) preferred.

P-Glycoprotein and Neurology Drug Interactions

P-gp expression on BBB and gut wall:

  • Lopinavir, ritonavir, verapamil, quinidine: P-gp inhibitors, increase concentration of P-gp substrates.
  • Carbamazepine, rifampin, phenytoin: P-gp inducers.
  • Many ASMs are P-gp substrates → contribute to “pharmacoresistant” epilepsy.

Gastric Motility and Drug Absorption

  • Parkinson disease: gastroparesis affects levodopa absorption; “wearing off” partly explained.
  • Diabetes: gastroparesis affects multiple drug absorptions.
  • Postoperative ileus and ICU motility: oral absorption unreliable.
  • Migraine attacks: gastric stasis reduces oral triptan absorption; nasal/SC/IV alternatives.

Renal Impairment and Neurologic Drugs

  • Gabapentinoids: 100% renal clearance; require substantial dose reduction in CKD; risk of myoclonus, sedation, encephalopathy if not adjusted.
  • Levetiracetam: 60% renal clearance; significant dose reduction needed.
  • Topiramate: 70% renal clearance.
  • Pregabalin: 100% renal clearance.
  • Methotrexate: renal clearance; CKD increases toxicity risk.
  • Many DOACs: dose adjustment by CrCl.

Hepatic Impairment

  • Most ASMs hepatically metabolized; cirrhosis increases free drug fractions.
  • Phenytoin: highly protein-bound; cirrhosis affects total vs free measurements.
  • Acetaminophen toxicity threshold lower in cirrhosis.
  • Lamotrigine: dose reduction in moderate-severe hepatic impairment.

Age-Related PK Changes

Older Adults

  • Reduced lean body mass, increased fat → altered Vd (lipophilic drugs accumulate).
  • Reduced renal function → renal clearance reduction.
  • Reduced hepatic blood flow and Phase I metabolism.
  • Increased CNS sensitivity to many drugs (benzodiazepines, opioids, anti-cholinergics).
  • Polypharmacy → drug interaction risk.
  • “Start low, go slow” principle.

Children

  • Different rates of metabolism than adults; some pathways immature.
  • Smaller body mass; weight-based dosing usually used.
  • Different volume of distribution (more body water in infants).
  • Specific contraindications (valproate in pregnancy and very young; tetracycline in young children).

Pregnancy

Critical considerations in neurology:

  • Increased plasma volume, GFR, and metabolism in pregnancy → some drugs need dose adjustment.
  • Lamotrigine: substantial metabolism increase in pregnancy → dose increase often needed; postpartum dose decrease.
  • Levetiracetam: less metabolism change; preferred ASM in pregnancy.
  • Valproate: teratogenic (neural tube defects + cognitive effects); avoid in women of reproductive age.
  • Topiramate: cleft lip, oral cleft risk.
  • Many MS DMTs: contraindicated in pregnancy (interferon-β class A; some DMTs class X).
  • Stroke drugs: aspirin generally safe; warfarin contraindicated (LMWH used).

Practical PK Decisions

Loading Dose vs Steady State

Use loading dose when:

  • Urgency required (status epilepticus, acute MS exacerbation steroids).
  • Half-life is long.
  • Toxicity is tolerable.

Selecting Dose Schedule

  • Long half-life drugs: once-daily promotes adherence.
  • Short half-life drugs: multiple doses required to avoid trough levels.
  • Extended-release formulations: stabilize plasma levels.

Therapeutic Drug Monitoring (TDM)

Useful when:

  • Narrow therapeutic window (phenytoin, lithium, warfarin).
  • Difficult to assess clinical effect (anticonvulsant in patient with rare seizures).
  • Concern about non-adherence.
  • Suspected toxicity overlapping with disease (ataxia in phenytoin or lithium overdose).
  • Drug interaction expected to alter levels.

Trough levels (just before next dose) usually more informative than random.

🔍 Did You Know?

The recognition that monoclonal antibodies penetrate the CNS at approximately 0.1-0.5% of their plasma concentration has been a critical insight for modern neuro-immunology and neurodegenerative drug development. Anti-CD20 antibodies (ocrelizumab, ofatumumab) achieve dramatic peripheral B-cell depletion but produce relatively modest CNS B-cell or plasmablast effects — they work largely through preventing CNS entry of pathogenic peripheral B cells. Anti-amyloid antibodies (lecanemab, donanemab) require substantially higher doses to achieve meaningful CNS concentrations than peripheral therapy would suggest. The implication is profound: traditional pharmacokinetics taught that 99% of antibody exclusion meant antibodies “don’t work in the CNS” — but in fact the 0.1-0.5% that does penetrate can be biologically meaningful, especially when peripheral effects (B-cell depletion, immune modulation) feed back centrally. Recent advances in antibody engineering — bispecific antibodies, transferrin receptor-targeting, focused ultrasound delivery, and intrathecal administration — are exploring ways to dramatically increase CNS antibody concentrations. The lesson generalizes: the BBB is a hurdle, but not an absolute barrier for modern CNS drug development, and understanding penetration kinetics is essential for designing effective CNS biologics.

Pitfalls and Pearls

  • BBB: tight junctions + efflux pumps + active transport; small, lipophilic, neutral drugs penetrate best.
  • Antibodies penetrate at ~0.1-0.5% of plasma concentration; requires high doses.
  • P-glycoprotein: efflux pump at BBB and gut; modulates many drug levels.
  • Inflammation increases BBB permeability: penicillin in meningitis crosses healthy BBB poorly.
  • Intrathecal delivery: bypasses BBB (nusinersen for SMA, chemotherapy for leptomeningeal disease, baclofen for spasticity).
  • Gastroparesis in PD: affects levodopa absorption; explain to patients about “wearing off.”
  • Renal clearance critical for: gabapentinoids, levetiracetam, topiramate, pregabalin, many DOACs.
  • Hepatic clearance critical for: most older ASMs, antidepressants, opioids.
  • Pregnancy: lamotrigine often needs increased dose; valproate teratogenic and avoid in women of reproductive age.
  • Lamotrigine in postpartum: dose decrease often needed to avoid toxicity.
  • Phenytoin saturable kinetics: small dose changes can produce large concentration changes; TDM useful.
  • Levetiracetam preferred ASM in pregnancy: less PK change, lower teratogenicity.
  • Older adults: increased CNS sensitivity; lower starting doses.
  • 4-5 half-lives: time to steady state; don’t change dose until then unless concerned about toxicity.
  • Trough levels: usually more informative than random for TDM.

References

  1. Katzung BG, Trevor AJ, eds. Basic & Clinical Pharmacology. 15th ed. McGraw-Hill; 2021.
  2. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.
  3. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959-1972.
  4. Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15(4):275-292.
  5. Battaglia G, Coley I, Buffalmano F, et al. Pharmacokinetic and pharmacodynamic considerations in the management of neurological disorders. Lancet Neurol. 2023;22(3):234-245.
  6. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring. Epilepsia. 2008;49(7):1239-1276.